Merck & Co., Inc., Kenilworth, NJ, USA.
BARDS Early Development Statistics - Early Oncology, 351 North Sumneytown Pike, North Wales, 19454, USA.
J Immunother Cancer. 2019 Feb 8;7(1):39. doi: 10.1186/s40425-019-0513-4.
In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these early efficacy metrics are still predictive of long-term clinical benefit such as overall survival. The goal of this paper is to identify appropriate early efficacy metrics predictive of overall survival for immunotherapy trials.
Based on several checkpoint blockade based immunotherapy studies in metastatic melanoma, we evaluated the predictive value of early tumor size changes and RECIST-based efficacy metrics at various time points on overall survival. The cut-off values for tumor size changes to predict survival were explored via tree based recursive partitioning and validated by external data. Sensitivity analyses were performed for the cut-offs.
The continuous tumor size change metric and RECIST-based trichotomized response metric at different landmark time points were found to be statistically significantly associated with overall survival. The predictive values were higher at Week 12 and 18 than those at Week 24. The percentage of tumor size changes appeared to have comparable or lower predictive values than the RECIST-based trichotomized metric, and a cut-off of approximately 10% tumor reduction appeared to be reasonable for predicting survival.
An approximate 10% tumor reduction may be a reasonable cut-off for early decision-making while the RECIST-based efficacy metric remains the primary tool. Early landmark analysis is especially useful for decision making when accrual is fast. Composite response rate (utilizing different weights for PR/CR and SD) may be worth further investigation.
Clinical trials gov, NCT01295827 , Registered February 15, 2011; NCT01704287 , Registered October 11, 2012; NCT01866319 , Registered May 31, 2013.
在肿瘤学临床开发中,客观缓解率、疾病控制率和早期肿瘤大小变化通常被用作早期决策的疗效指标。然而,对于免疫疗法试验,尚不清楚这些早期疗效指标是否仍然可以预测总生存期等长期临床获益。本文的目的是确定可预测免疫疗法试验总生存期的适当早期疗效指标。
基于几项转移性黑色素瘤的基于检查点阻断的免疫治疗研究,我们评估了不同时间点的早期肿瘤大小变化和基于 RECIST 的疗效指标对总生存期的预测价值。通过基于树的递归分区探索了肿瘤大小变化预测生存的截止值,并通过外部数据进行了验证。对截止值进行了敏感性分析。
连续的肿瘤大小变化指标和不同里程碑时间点的基于 RECIST 的三分类反应指标与总生存期呈统计学显著相关。在第 12 周和第 18 周的预测值高于第 24 周。肿瘤大小变化的百分比似乎具有与基于 RECIST 的三分类指标相当或更低的预测值,并且约 10%的肿瘤缩小似乎是预测生存的合理截止值。
大约 10%的肿瘤缩小可能是早期决策的合理截止值,而基于 RECIST 的疗效指标仍然是主要工具。早期里程碑分析对于快速入组时的决策制定特别有用。复合反应率(对 PR/CR 和 SD 采用不同权重)可能值得进一步研究。
Clinicaltrials.gov,NCT01295827,注册于 2011 年 2 月 15 日;NCT01704287,注册于 2012 年 10 月 11 日;NCT01866319,注册于 2013 年 5 月 31 日。